Abstract
Purpose Risk factors for coronavirus disease 2019 (COVID-19) mortality include older age, cardiovascular disease, diabetes, and other comorbidities. Latent class analysis (LCA) can identify unrecognized morbidity patterns for decedents with COVID-19.
Methods Data were collected from 23 U.S. jurisdictions about decedents with COVID-19 early in the COVID-19 pandemic (February 12–May 12, 2020). LCA identified groups of individuals based upon pre-existing comorbidities: cardiovascular, renal, lung, neurologic, and liver disease; obesity; diabetes; and immunocompromised state. Results were stratified by sex, age, race/ethnicity, and location of death.
Results Of 12,340 decedents, LCA identified three classes, which included classes with prominent cardiovascular disease and diabetes (32%), prominent cardiovascular disease without diabetes (19%), and a “minimal prevalence” class (49%) with a low frequency of comorbidities. Individuals in the “minimal prevalence” class had risk factors in <2 comorbidity groups, where cardiovascular disease was the most common for individuals with a single comorbidity.
Conclusions LCA analysis reaffirms the importance of diabetes and cardiovascular disease as risk factors for COVID-19 mortality and indicates that about half of decedents were in the “minimal prevalence” group. Results could guide vaccination and treatment messaging to groups with no or few underlying conditions.
Disclaimer The conclusions, findings, and opinions expressed by the authors do not necessarily reflect the offical position of the Centers for Disease Control and Prevention or the authors’ affililated institutions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. See manuscript text for further details.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
CRediT roles: David A. Siegel: Original draft preparation, Visualization, Conceptualization, Methodology, Writing-Reviewing and Editing
Mona Saraiya: Conceptualization, Methodology, Writing-Reviewing and Editing
Emily Koumans, Carolyn V. Gould: Supervision, Conceptualization, Visualization, Methodology, Writing-Reviewing and Editing
William Bentley, Rongxia Li: Methodology, Visualization, Formal Analysis, Writing-Reviewing and Editing
David McCormick: Methodology, Visualization, Writing-Reviewing and Editing
Paul Rashad Young, Jonathan Wortham: Methodology, Writing-Reviewing and Editing
All other authors (Joseph McLaughlin, Anjali Vyas, Charles R. Clark, Gillian Richardson, Anna Krueger, Stacy Holzbauer, Leslie Kollmann. Deepam Thomas, Mojisola Ojo, Marc Paladini, Kathleen H. Reilly, Meagan McLafferty, Dean E. Sidelinger, Laura C. Chambers, Jennifer S. Read): Data curation, Visualization, Writing-reviewing and editing
No conflicts of interests are noted.
Data Availability
Underlying data are not publicly available with personal identifiable information due to privacy and legal restrictions.
Abbreviations
- (CDC)
- Centers for Disease Control and Prevention
- (COVID-19)
- Coronavirus disease 2019
- (HIV)
- Human immunodeficiency virus
- (LCA)
- Latent class analysis
- (PCR)
- Polymerase chain reaction
- (SARS-CoV-2)
- Severe acute respiratory syndrome coronavirus 2
